Advisory Research Inc Fibrogen Inc Transaction History

Advisory Research Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$35.13 - $55.53 $714,122 - $1.13 Million	-20,328 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$42.83 - $59.91 $238,091 - $333,039	-5,559 Reduced 21.47%	20,328 $1.11 Million
Q4 2018 Feb 13, 2019	BUY	$37.97 - $60.16 $123,516 - $195,700	3,253 Added 14.37%	25,887 $1.2 Million
Q3 2018 Nov 13, 2018	BUY	$56.3 - $67.25 $1.27 Million - $1.52 Million	22,634 New	22,634 $1.38 Million
Q4 2017 Feb 08, 2018	SELL	$41.95 - $60.1 $1.01 Million - $1.44 Million	-23,976 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$33.4 - $53.9 $800,798 - $1.29 Million	23,976	23,976 $1.29 Million

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Advisory Research Inc, based on Form 13F filings with the SEC.

Stay updated on Advisory Research Inc with notifications on news.